Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma

Cancer Investigation

Volumn 29, Issue 1, 2011, Pages 49-55

  Ahrar, Judy ^a   Gupta, Sanjay ^a   Ensor, Joe ^b   Ahrar, Kamran ^a   Madoff, David C ^a   Wallace, Michael J ^a   Murthy, Ravi ^a   Tam, Alda ^a   Hwu, Patrick ^a   Bedikian, Agop Y ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Melanoma Medical Oncology ^*  (United States)

Author keywords

Cutaneous melanoma; Hepatic artery chemoembolization; Liver metastases

Indexed keywords

CARBOPLATIN; CISPLATIN; DACARBAZINE; LACTATE DEHYDROGENASE; PACLITAXEL; VINBLASTINE;

ARTICLE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; FEMALE; HEPATIC ARTERY CHEMOEMBOLIZATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE-FREE SURVIVAL; FEMALE; HEPATIC ARTERY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; TEXAS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650423886     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.535052     Document Type: Article

References (30)

1. Hall HI, Miller DR, Rogers JD, Bewerse B. Update on the incidenceand mortality from melanoma in the United States. J AmAcad Dermatol 1999;40:35-42.
2. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneousmelanoma incidence among whites in the United States. JNatl Cancer Inst 2001;93:678-683. (Pubitemid 32492808)
3. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasingburden of melanoma in the United States. J Invest Dermatol2009;129:1666-1674.
4. Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C,Schadendorf D, Steinmann A, Wittenberg G, Lieb W, BröckerEB. Treatment of disseminated ocular melanoma with sequentialfotemustine, interferon alpha, and interleukin 2. Br J Cancer2002;87:840-845.
5. Leiter U, Meier F, Schittek B, Garbe C.The natural course of cutaneousmelanoma. J Surg Oncol 2004;86:172-178.
6. Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatmentoptions for patients with ocular melanoma metastatic to the liver.Ann Surg Oncol 2004;11:290-297.
7. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, FinnSM, Munzenrider JE, Spar MD. Survival of patients with metastasesfrom uveal melanoma. Ophthalmology 1991;98:383-389;discussion 390.
8. Pyrhonen S. The treatment of metastatic uveal melanoma. Eur JCancer 1998;34(Suppl. 3):S27-S30.
9. Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinantsof outcome following locoregional or distant recurrencein patients with cutaneous melanoma. Ann Surg Oncol2008;15:1476-1484.
10. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521melanoma patients with distant metastases. J Am Coll Surg 1995;181:193-201.
11. Agarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomizedtrial of intrahepatic arterial infusion chemotherapy with cisplatinand chemoembolization with cisplatin and polyvinyl sponge inpatients with ocular melanoma metastatic to the liver. MelanomaRes 2004;14:217-222.
12. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S,Plager C, Papadopoulos N, Benjamin RS. Treatment of uvealmelanoma metastatic to the liver: a review of the M. D. AndersonCancer Center experience and prognostic factors. Cancer1995;76:1665-1670.
13. Carrasco CH, Wallace S, Charnsangavej C, Papadopoulos NE,Patt YZ, Mavligit GM. Treatment of hepatic metastases in ocularmelanoma. Embolization of the hepatic artery with polyvinylsponge and cisplatin. JAMA 1986;255:3152-3154.
14. Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, ShieldsJA, Sato T. Chemoembolization of the hepatic artery with BCNUfor metastatic uveal melanoma: results of a phase II study.Melanoma Res 2005;15:297-304.
15. Sharma KV, Gould JE, Harbour JW, Linette GP, Pilgram TK,Dayani PN, Brown DB. Hepatic arterial chemoembolization formanagement of metastatic melanoma. AJR Am J Roentgenol2008;190:99-104.
16. Vogl T, Eichler K, Zangos S, Herzog C, Hammerstingl R,Balzer J, Gholami A. Preliminary experience with transarterialchemoembolization (TACE) in liver metastases of uveal malignantmelanoma: local tumor control and survival. J Cancer ResClin Oncol 2007;133:177-184.
17. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, BenjaminRS, Wallace S. Regression of ocular melanoma metastatic to theliver after hepatic arterial chemoembolization with isplatin andpolyvinyl sponge. JAMA 1988;260:974-976.
18. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocularmelanoma. Cancer 1983;52:334-336.
19. Siegel R, Hauschild A, Kettelhack C, Kahler KC, Bembenek A,Schlag PM. Hepatic arterial Fotemustine chemotherapy in patientswith liver metastases from cutaneous melanoma is as effectiveas in ocular melanoma. Eur J Surg Oncol 2007;33:627-632.
20. Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC,Wallace MJ, Murthy R, Tam A, Hwu P. Hepatic artery chemoembolizationin patients with ocular melanoma metastatic to theliver: response, survival, and prognostic factors. Am J Clin Oncol2009.
21. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, DorvalT, Meuli R, Gillet M, Lejeune F, Zografos L. Treatment of ocularmelanoma metastatic to the liver by hepatic arterial chemotherapy.J Clin Oncol 1997;15:2589-2595.
22. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, DurantJR. Amultifactorial analysis of melanoma. IV. Prognostic factorsin 200 melanoma patients with distant metastases (stage III).J Clin Oncol 1983;1:126-134.
23. Meyer T, Merkel S, Goehl J, Hohenberger W. Surgical therapyfor distant metastases of malignant melanoma. Cancer2000;89:1983-1991.
24. Kolmel KF, Kulle B, Lippold A, Seebacher C. Survival probabilitiesand hazard functions of malignant melanoma in Germany1972-1996, an analysis of 10433 patients. Evolution of gender differences and malignancy. Eur J Cancer 2002;38:1388-1394.
25. Masback A, Olsson H, Westerdahl J, Ingvar C, Jonsson N.Prognostic factors in invasive cutaneous malignant melanoma:a population-based study and review. Melanoma Res 2001;11:435-445.
26. Schmoeckel C, Braun-Falco O. Prognostic index in malignantmelanoma. Arch Dermatol 1978;114:871-873.
27. Ahmed I.Malignant melanoma: prognostic indicators.Mayo ClinProc 1997;72:356-361.
28. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, MadoffDC, McRae SE, HicksME, Rao S, Vauthey JN, Ajani JA, Yao JC.Hepatic arterial embolization and chemoembolization for thetreatment of patients with metastatic neuroendocrine tumors:variables affecting response rates and survival. Cancer 2005;104:1590-1602.
29. Kobayashi K, Gupta S, Trent JC, Vauthey JN, Krishnamurthy S,Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, McRae SE,Hicks ME. Hepatic artery chemoembolization for 110 gastrointestinalstromal tumors: response, survival, and prognostic factors.Cancer 2006;107:2833-2841.
30. Yamashita Y, Takahashi M, Koga Y, Saito R, Nanakawa S,Hatanaka Y, Sato N, Nakashima K, Urata J, Yoshizumi K, ItoK, Sumi S. Prognostic factors in liver metastases after transcatheterarterial embolization or arterial infusion. Acta Radiol1990;31:269-274.